Merck & Co., Inc. Financial Highlights Package First Quarter 2022 Table of Contents Table 1: GAAP P&L..........................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter......2 Table 2a: GAAP to Non-GAAP Reconciliation 1Q22 ........................3 Table 2b: GAAP to Non-GAAP Reconciliation 1Q21.........................4 Table 3: Sales – Current Year and Prior Year by Quarter ...............5 Table 3a: Sales – U.S. / Ex- U.S. 1Q22.............................................6 Table 3b: Sales – Pharmaceutical Geographic Split .........................7 Table 4: Other (Income) Expense ....................................................8 -- 1 of 9 -- Sales 15,901 $ 10,627 $ 50% Costs, Expenses and Other Cost of sales 5,380 3,199 68% Selling, general and administrative 2,323 2,187 6% Research and development 2,576 2,412 7% Restructuring costs 53 297 -82% Other (income) expense, net 708 (455) * Income from Continuing Operations Before Taxes 4,861 2,987 63% Income Tax Provision 554 238 Net Income from Continuing Operations 4,307 2,749 57% Less: Net (Loss) Income Attributable to Noncontrolling Interests (3) 4 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 4,310 2,745 57% Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests - 434 * Net Income Attributable to Merck & Co., Inc. 4,310 $ 3,179 $ 36% Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.70 $ 1.08 $ 57% Income from Discontinued Operations - 0.17 * Net Income 1.70 $ 1.26 $ 35% Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.70 $ 1.08 $ 57% Income from Discontinued Operations - 0.17 * Net Income 1.70 $ 1.25 $ 36% Average Shares Outstanding 2,528 2,531 Average Shares Outstanding Assuming Dilution 2,537 2,541 Tax Rate from Continuing Operations 11.4% 8.0% * 100% or greater MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon). The historical results of the businesses that were contributed to Organon in the spin-off are excluded from sales and expenses below and reflected as discontinued operations in the company’s Consolidated Statements of Income provided below. 1Q21 GAAP % Change 1Q22 1 -- 2 of 9 -- Sales 15,901 $ 10,627 $ 11,402 $ 13,154 $ 13,521 $ 48,704 $ 50% Costs, Expenses and Other Cost of sales 5,380 3,199 3,104 3,450 3,873 13,626 68% Selling, general and administrative 2,323 2,187 2,281 2,336 2,830 9,634 6% Research and development 2,576 2,412 4,321 2,445 3,068 12,245 7% Restructuring costs 53 297 82 107 174 661 -82% Other (income) expense, net 708 (455) (103) (450) (333) (1,341) * Income from Continuing Operations Before Taxes 4,861 2,987 1,717 5,266 3,909 13,879 63% Income Tax Provision 554 238 503 695 85 1,521 Net Income from Continuing Operations 4,307 2,749 1,214 4,571 3,824 12,358 57% Less: Net (Loss) Income Attributable to Noncontrolling Interests (3) 4 1 4 4 13 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 4,310 2,745 1,213 4,567 3,820 12,345 57% Income (Loss) from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests - 434 332 - (62) 704 * Net Income Attributable to Merck & Co., Inc. 4,310 $ 3,179 $ 1,545 $ 4,567 $ 3,758 $ 13,049 $ 36% Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.70 $ 1.08 $ 0.48 $ 1.81 $ 1.51 $ 4.88 $ 57% Income (Loss) from Discontinued Operations - 0.17 0.13 - (0.02) 0.28 * Net Income 1.70 $ 1.26 $ 0.61 $ 1.81 $ 1.49 $ 5.16 $ 35% Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: Income from Continuing Operations 1.70 $ 1.08 $ 0.48 $ 1.80 $ 1.51 $ 4.86 $ 57% Income (Loss) from Discontinued Operations - 0.17 0.13 - (0.02) 0.28 * Net Income 1.70 $ 1.25 $ 0.61 $ 1.80 $ 1.48 $ 5.14 $ 36% Average Shares Outstanding 2,528 2,531 2,533 2,530 2,527 2,530 Average Shares Outstanding Assuming Dilution 2,537 2,541 2,540 2,536 2,535 2,538 Tax Rate from Continuing Operations 11.4% 8.0% 29.3% 13.2% 2.2% 11.0% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. Table 1a MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) % Change 1Q 2022 1Q 1Q 2Q 3Q 4Q Full Year 2021 2 -- 3 of 9 -- First Quarter Cost of sales 5,380 $ 680 46 726 4,654 $ Selling, general and administrative 2,323 50 21 71 2,252 Research and development 2,576 22 7 29 2,547 Restructuring costs 53 - 53 53 - Other (income) expense, net 708 (115) 684 569 139 Income from Continuing Operations Before Taxes 4,861 (637) (127) (684) (1,448) 6,309 Income Tax Provision (Benefit) 554 (155) (3) (22) (3) (152) (3) (329) 883 Net Income from Continuing Operations 4,307 (482) (105) (532) (1,119) 5,426 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 4,310 (482) (105) (532) (1,119) 5,429 Earnings per Common Share Assuming Dilution from Continuing Operations 1.70 $ (0.19) (0.04) (0.21) (0.44) 2.14 $ Tax Rate 11.4% 14.0% Only the line items that are affected by non-GAAP adjustments are shown. Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, primarily reflect royalty income and a decrease in the estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Adjustment Subtotal MERCK & CO., INC. FIRST QUARTER 2022 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2a 3 -- 4 of 9 -- First Quarter Cost of sales 3,199 $ 497 27 188 (3) 712 2,487 $ Selling, general and administrative 2,187 10 3 13 2,174 Research and development 2,412 18 7 25 2,387 Restructuring costs 297 297 297 - Other (income) expense, net (455) (28) (561) (589) 134 Income from Continuing Operations Before Taxes 2,987 (497) (334) 561 (188) (458) 3,445 Income Tax Provision (Benefit) 238 (89) (4) (41) (4) 123 (4) (249) (4) (256) 494 Net Income from Continuing Operations 2,749 (408) (293) 438 61 (202) 2,951 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 2,745 (408) (293) 438 61 (202) 2,947 Earnings per Common Share Assuming Dilution from Continuing Operations 1.08 $ (0.16) (0.11) 0.17 0.02 (0.08) 1.16 $ Tax Rate 8.0% 14.3% Only the line items that are affected by non-GAAP adjustments are shown. Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non- GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, primarily reflect royalty income, partially offset by an increase in the estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents a charge for the discontinuation of COVID-19 development programs. (4) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items also includes a $208 million net tax benefit related to the settlement of certain federal income tax matters. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items Adjustment Subtotal MERCK & CO., INC. FIRST QUARTER 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are excluded from the financial information provided below. 4 -- 5 of 9 -- 2022 1Q 1Q 2Q 3Q 4Q Full Year Nom % Ex-Exch % TOTAL SALES (1) $15,901 $10,627 $11,402 $13,154 $13,521 $48,704 50 52 PHARMACEUTICAL 14,107 9,238 9,980 11,496 12,039 42,754 53 57 Oncology Keytruda 4,809 3,899 4,176 4,534 4,577 17,186 23 27 Alliance Revenue – Lynparza (2) 266 228 248 246 268 989 17 20 Alliance Revenue – Lenvima (2) 227 130 181 188 206 704 75 77 Alliance Revenue – Reblozyl (3) 52 17 17 * * Vaccines (4) Gardasil / Gardasil 9 1,460 917 1,234 1,993 1,528 5,673 59 60 ProQuad / M-M-R II / Varivax 470 449 516 661 509 2,135 5 6 RotaTeq 216 158 208 227 213 807 36 38 Pneumovax 23 173 171 152 277 292 893 1 3 Vaqta 36 34 56 48 41 179 6 6 Hospital Acute Care Bridion 395 340 387 369 436 1,532 16 20 Prevymis 94 82 93 96 100 370 14 20 Primaxin 58 65 60 70 65 259 -10 -11 Noxafil 57 67 66 64 62 259 -14 -11 Cancidas 53 57 54 56 45 212 -8 -7 Dificid 52 27 34 54 60 175 95 96 Invanz 52 57 48 53 45 202 -7 -4 Zerbaxa 30 (8) (1) (2) 10 (1) * * Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 72 74 74 100 94 342 -3 -3 Adempas (6) 61 55 74 59 63 252 11 20 Virology Lagevrio 3,247 952 952 * * Isentress / Isentress HD 158 209 192 189 178 769 -24 -21 Neuroscience Belsomra 69 79 78 81 80 318 -14 -8 Immunology Simponi 186 214 202 203 206 825 -13 -6 Remicade 61 85 75 73 67 299 -29 -21 Diabetes (7) Januvia 779 809 784 852 878 3,324 -4 -1 Janumet 454 486 477 487 514 1,964 -6 -1 Other Pharmaceutical (8) 520 554 512 518 533 2,118 -6 -5 ANIMAL HEALTH 1,482 1,418 1,472 1,417 1,261 5,568 4 9 Livestock 832 819 821 864 791 3,295 2 7 Companion Animals 650 599 651 553 470 2,273 9 13 Other Revenues (9) 312 (29) (50) 241 221 382 * * * 200% or greater (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $1,305 million in the first quarter of 2022 and $1,363 million, $1,330 million, $1,417 million, and $1,475 million in the first, second, third, and fourth quarter of 2021, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues in the first and third quarter of 2021 include $50 million and $135 million, respectively, related to the receipt of milestone payments for an out-licensed product. Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance revenue represents royalties and a milestone payment. (4) Total Vaccines sales were $2,481 million in the first quarter of 2022 and $1,809 million, $2,293 million, $3,315 million and $2,715 million in the first, second, third and fourth quarters of 2021, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 2021 1Q MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 5 -- 6 of 9 -- 1Q 2022 1Q 2021 % Change 1Q 2022 1Q 2021 % Change 1Q 2022 1Q 2021 % Change TOTAL SALES (1) $15,901 $10,627 50 $7,339 $4,790 53 $8,563 $5,837 47 PHARMACEUTICAL 14,107 9,238 53 6,773 4,294 58 7,334 4,944 48 Oncology Keytruda 4,809 3,899 23 2,779 2,181 27 2,030 1,718 18 Alliance Revenue - Lynparza (2) 266 228 17 141 118 19 125 110 14 Alliance Revenue - Lenvima (2) 227 130 75 156 85 83 71 44 60 Alliance Revenue - Reblozyl (3) 52 * 27 * 25 * Vaccines (4) Gardasil / Gardasil 9 1,460 917 59 418 313 34 1,042 604 72 ProQuad / M-M-R II / Varivax 470 449 5 371 333 11 99 117 -15 RotaTeq 216 158 36 175 118 48 41 41 1 Pneumovax 23 173 171 1 118 73 62 55 99 -44 Vaqta 36 34 6 29 25 16 7 9 -24 Hospital Acute Care Bridion 395 340 16 195 167 17 199 173 15 Prevymis 94 82 14 40 35 13 54 47 15 Primaxin 58 65 -10 1 * 58 65 -10 Noxafil 57 67 -14 10 15 -35 48 52 -9 Cancidas 53 57 -8 1 3 -47 52 55 -6 Dificid 52 27 95 49 25 99 3 2 49 Invanz 52 57 -7 1 4 -80 52 52 -2 Zerbaxa 30 (8) * 18 (2) * 12 (6) * Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 72 74 -3 71 68 4 1 6 -82 Adempas (6) 61 55 11 61 55 11 Virology Lagevrio 3,247 * 1,523 * 1,723 * Isentress / Isentress HD 158 209 -24 61 71 -13 97 138 -30 Neuroscience Belsomra 69 79 -14 20 18 13 48 61 -21 Immunology Simponi 186 214 -13 186 214 -13 Remicade 61 85 -29 61 85 -29 Diabetes (7) Januvia 779 809 -4 325 348 -7 454 461 -1 Janumet 454 486 -6 63 84 -25 391 401 -3 Other Pharmaceutical (8) 520 554 -6 181 212 -15 339 341 -1 ANIMAL HEALTH 1,482 1,418 4 473 437 8 1,009 981 3 Livestock 832 819 2 171 157 9 661 662 - Companion Animals 650 599 9 302 280 8 348 319 9 Other Revenues (9) 312 (29) * 93 59 57 220 (88) * * 200% or greater Sum of U.S. plus international may not equal global due to rounding. (9) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues in the first quarter of 2021 include $50 million related to the receipt of a milestone payment for an out-licensed product. Global U.S. International (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties and a milestone payment. (4) Total Vaccines sales were $2,481 million in the first quarter of 2022 and $1,809 million in the first quarter of 2021. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $1,305 million in the first quarter of 2022 and $1,363 million in the first quarter of 2021. (8) Includes Pharmaceutical products not individually shown above. Table 3a MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS FIRST QUARTER 2022 (AMOUNTS IN MILLIONS) (UNAUDITED) 6 -- 7 of 9 -- 2022 % Change TOTAL PHARMACEUTICAL $14,107 $9,238 $9,980 $11,496 $12,039 $42,754 53 United States 6,773 4,294 4,647 5,670 5,790 20,401 58 % Pharmaceutical Sales 48.0% 46.5% 46.6% 49.3% 48.1% 47.7% Europe (1) 3,309 2,276 2,404 2,445 2,655 9,780 45 % Pharmaceutical Sales 23.5% 24.6% 24.1% 21.3% 22.1% 22.9% China 1,113 688 944 1,278 1,352 4,262 62 % Pharmaceutical Sales 7.9% 7.4% 9.5% 11.1% 11.2% 10.0% Japan 965 607 637 614 771 2,629 59 % Pharmaceutical Sales 6.8% 6.6% 6.4% 5.3% 6.4% 6.1% Asia Pacific (other than China and Japan) 786 437 442 450 488 1,817 80 % Pharmaceutical Sales 5.6% 4.7% 4.4% 3.9% 4.1% 4.2% Eastern Europe/Middle East/Africa 450 357 318 362 278 1,315 26 % Pharmaceutical Sales 3.2% 3.9% 3.2% 3.1% 2.3% 3.1% Latin America 435 353 379 434 421 1,587 23 % Pharmaceutical Sales 3.1% 3.8% 3.8% 3.8% 3.5% 3.7% Canada 189 160 157 164 167 650 18 % Pharmaceutical Sales 1.3% 1.7% 1.6% 1.4% 1.4% 1.5% Other 87 66 52 79 117 313 32 % Pharmaceutical Sales 0.6% 0.8% 0.4% 0.8% 0.9% 0.8% 1Q Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. 1Q 1Q 2Q 3Q 4Q Full Year 2021 MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b 7 -- 8 of 9 -- OTHER (INCOME) EXPENSE, NET 1Q22 1Q21 Interest income (7) $ (11) $ Interest expense 243 200 Exchange losses 39 41 Loss (income) from investments in equity securities, net (1) 708 (574) Net periodic defined benefit plan cost (credit) other than service cost (121) (89) Other, net (154) (22) Total 708 $ (455) $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 8 -- 9 of 9 --